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The Correlation Between Neuropathy Limitations and Depression
in Chemotherapy Patients
Melissa Thebeau
ABSTRACT

This study examined the association between neuropathy limitations and
depression in chemotherapy patients currently on treatment with a taxane-based,
platinum-based or plant alkaloid chemotherapy drug.
The Overall Neuropathy Limitations Scale (ONLS) and the Beck Depression
Inventory-Short Form (BDI-SF) were used to assess neuropathy limitations and
depression in 24 chemotherapy patients with reported symptoms of peripheral
neuropathy. Average age of patients was 65 years, 66.6% were female, and average
number of chemotherapy cycles completed was 5.6. Of the 24 patients, 37.5% of patients
were on a single agent taxane-based drug, 37.5% of patients were on a taxane-based drug
with a platinum based drug, 16.6% of patients were on a plant alkaloid, and 8.3% were on
a combination of a taxane-based and another non-neurotoxic chemotherapy drug.
The scores on both the BDI-SF and ONLS were very low. The mean score on the
BDI-SF was 4.1 with a standard deviation of 2.7. The mean score on the ONLS was 2.2
with a standard deviation of 1.5. The study showed a non-significant relationship
between neuropathy limitations and depression in chemotherapy patients.
These findings show no association between neuropathy limitations and
depression. Although all of these patients had symptoms of peripheral neuropathy, they
were not severe enough to interfere with daily activities. The lack of relationship was not
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unexpected given the low scores on both the BDI-SF and ONLS. Future research should
re-evaluate this relationship with a larger, more diverse sample.
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Chapter One Introduction

Cancer accounts for nearly a quarter of deaths in the United States each year, only
outranked by heart disease. In 2009, there were an estimated 1,479,350 new cancer cases
diagnosed (American Cancer Society, 2010). Of these patients, nearly half of them will
receive chemotherapy treatment. Scientists have made a great deal of progress in
developing treatments to manage the potential side effects of chemotherapy. Common
chemotherapy side effects include infections, nausea and vomiting, hair loss,
constipation, diarrhea, fatigue, and nerve damage. Of particular concern, these side
effects may lead to problems of adherence to treatment and diminished quality of life
(Gralla, Houlihan, & Messner, 2010).
One of the side effects of chemotherapy, nervous system damage, can present
with a unique set of complications. Peripheral neuropathy (PN) is a complication that
patients experience when the chemotherapy drugs damage their nerves. It is often
characterized by pain, numbness, and tingling in the hands and feet (Gralla, Houlihan, &
Messner, 2010). Types of chemotherapy treatments that commonly cause PN include:
taxanes like paclitaxel, docetaxel and abraxane; platinum drugs such as cisplatin and
oxaliplatin; and plant alkaloids such as vincristine, vinorelbine and vinblastine (American
Cancer Society, 2010). PN may present as pain, numbness and tingling in the
extremities. Ototoxicity, changes in vision, blood pressure, and gastrointestinal function
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infrequently occur (Bakitas, 2007). These conditions may cause limitations in a patient’s
daily activities.
Although effective chemotherapy treatments have been discovered, PN continues
to be a common complication affecting nerves including the sensory, motor, and
autonomic systems (Stitham, 2008). The limitations that PN cause have the potential to
add an increased level of stress and possible anxiety to cancer patients who already are
managing many new issues. Individuals who are experiencing PN may be unable to
perform many tasks independently, and may be at a higher risk for depression.
There are several factors that put a cancer patient at risk for depression. Some of
these risk factors include living with the disease, medications that are prescribed to
manage the cancer and side effects, poor support systems, and unrelieved symptoms such
as pain (Hamilton, 2005). A paucity of research has been conducted to determine the
effect of peripheral neuropathy symptoms on the mental health of those diagnosed with
cancer.
Problem Statement
Currently, there is little or no research focusing on the relationship between
limitations of chemotherapy induced peripheral neuropathy and depressive symptoms.
The purpose of this study was to determine whether there is a relationship between the
physical limitations of chemotherapy induced peripheral neuropathy experienced by
patients with cancer and depressive symptoms.
This study explored whether patients who are currently under treatment with a
taxane-based, platinum-based or plant alkaloid chemotherapy and who are suffering from
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limitations of chemotherapy induced peripheral neuropathy have an increased risk of
depressive symptoms.

Research Questions
The following questions guided this study:
1. What is the level of depression symptomatology experienced by cancer patients
receiving neurotoxic chemotherapy?
2. What is the level of neuropathy limitations in patients receiving neurotoxic
chemotherapy?
3. What is the relationship between depressive symptoms and the level of neuropathy
limitations in patients receiving neurotoxic chemotherapy?
Definition of Terms
The following terms are defined for purposes of this study:
Peripheral Neuropathy – Occurs when nerves are damaged or destroyed and cannot send
messages from the brain and spinal cord to the muscles, skin, and other parts of the body.
Symptoms often include: a sensation of wearing an invisible glove or sock, burning
sensation or freezing pain, sharp jabbing or electric-like pain, extreme sensitivity to
touch, difficulty sleeping because of feet and leg pain, loss of balance and coordination,
muscle weakness, difficulty walking or moving the arms, and may include unusual
sweating, and abnormalities in blood pressure or pulse. (Miller, 2007)
Neuropathy Limitations – Limitations from neuropathy are caused from damaged nerves
in the sensory, motor and autonomic systems. These may cause sensation changes, an
inability to determine joint position which causes lack of coordination, loss of dexterity,
cramps, falling from legs buckling or tripping over toes. It may cause lack of dexterity,
3

such as being unable to button a shirt, and lack of muscle control. Heat or cold
intolerance, blurred vision, feeling dizzy and/or fainting, and feelings of incomplete
bladder emptying. (Stitham, 2008)
Depression – A mood disorder marked by loss of interest or pleasure in living. A feeling
of sadness. (Davis, 2001)
Depressive Symptoms – Symptoms of depression may include persistent sadness,
hopelessness, loss of energy, irritability, excessive sleep or decreased interest in daily
activities. (Davis, 2001)
Significance of the Study
This study investigates a possible relationship between limitations from
chemotherapy induced peripheral neuropathy and depression. PN may cause pain and
alter patients’ activities of daily living. As patients’ lose independence with daily
activities they may become depressed. Symptoms of PN may limit the ability for an
individual to remain independent in activities of daily living. The more severe the
symptoms of PN become, the more depressed a person may feel. These feelings of
depression may lead to non-adherence with treatment, or diminished quality of life. An
analysis of previous studies found that depressed patients are three times less likely to
comply with treatments than patients who are not depressed (McManamy, 2009).

4

Chapter Two Review of Literature
This chapter presents the review of literature relevant to this study. The review of
literature describes the symptoms of patients with peripheral neuropathy (PN) and the
effect PN has on quality of life. This reviews empiric evidence of the effects of
chemotherapy on a patient’s emotional status, and having PN and depressive symptoms.
Through research, nurses may better understand the relationship between having
symptoms of PN and depressive symptoms for patients receiving chemotherapy.
Peripheral Neuropathy and Cancer
Little is known about the development of peripheral neuropathy. Depending on
the chemotherapy, PN side effects can range from a sensory and painful neuropathy to a
mixed sensory-motor neuropathy with or without autonomic nervous system involvement
(Sioka & Kyritsis, 2008). These investigators reviewed the neurotoxicity induced by
some of the most common chemotherapeutic agents. The platinum-based drugs were
found to cause pure sensory neuropathies, the taxane-based drugs caused a mixed sensory
and motor neuropathy, and the plant alkaloids caused both mixed sensory-motor and
autonomic neuropathies.
Bakitas (2007) interviewed 28 patients undergoing a variety of different
chemotherapy regimens in order to describe the experience and the influence of PN
symptoms on everyday life. Patients reported taxane-based chemotherapy induced
peripheral neuropathy as one of the most distressing treatment-related symptoms and a
5

major cause of alterations in function and quality of life. Some participants described the
pain as annoying, distracting, and unpleasant. When asked about functional ability,
patients rated the discomfort as a three or four out of ten. When asked how much the PN
complicated everyday activities, patients rated it as a seven or eight out of ten. PN
interrupts dressing, putting on jewelry, balance, and driving (Bakitis, 2007). Emotional
distress was attributed to having to deal with physical symptoms of PN, as well as
functional and social limitations.
Peripheral Neuropathy and Diabetes
Diabetic peripheral neuropathy (DPN) is a common symptom experienced by
those with advanced diabetes. Individuals diagnosed with diabetes are not included in
this study; however, those suffering from PN may report similar symptoms. In order to
demonstrate the burden of PN, three studies were reviewed.
Argoff, Cole, Fishbain, Irving and Mmed (2006) reviewed the current knowledge
about diabetic peripheral neuropathy pain (DPNP). They found that up to 50% of
diabetic patients experienced some degree of PN. Nearly a third of those with type 1
diabetes and more than half of those with type 2 diabetes mellitus (DM) had at least one
neuropathic symptom. Patients with type 2 DM were more likely to have paresthesia
and/or burning pain. The most common presentation of DPNP is pain or tingling in the
feet.
Tolle, Xu, and Sadosky (2005) completed a study to determine the burden of
DPNP. One-hundred and forty patients with DPNP completed a questionnaire that was
focused on pain intensity and impact of functioning. Of the patients who participated,
57% reported moderate pain and 25% reported severe pain. Overall, 91% of the patients
6

reported using prescription medication for their DPNP. Use of medications for anxiety,
depression, or sleep disturbances were reported for nearly half of the patients. This
study concluded that DPNP is associated with substantial patient burden resulting from
interference with daily functioning.
The final study (Hoffman, Sadosky, & Alvir, 2008) examined functional and
health status impairments among patients with DPNP. The study was conducted in 19
countries and included 401 diabetic patients with DPNP. Patients reported DPNP to be
more severe at night and stated that it frequently disrupts sleep. The study also showed
that PN is associated with major life disturbances including more physician office visits,
interference with daily activities such as ambulating and sleeping, and interference at
work.
Depression and Cancer
Depression in cancer patients is not yet completely understood. It is not clear
whether the depression contributes to the cancer, or whether the stress of having cancer
causes the depression. No matter how they happen, cancer and depression seem to cocoincide. The studies conducted in this area demonstrate that the acceptance of an
adjuvant chemotherapy regimen relies heavily on whether or not the patient is depressed
(Colleoni, et al., 2000). Patients who undergo initial diagnosis of cancer may become
depressed, which can interfere with treatment decisions and adherence to therapy. These
patients may have poorer outcomes because symptoms of depression include fatigue, loss
of appetite and insomnia. All of these symptoms make it difficult to continue treatment.
Results of the study suggested that depression represents a crucial factor for initial
acceptance of adjuvant chemotherapy, and that by treating the patient’s depression,
7

practitioners may improve the patients’ overall prognosis. One study (Watson et al.,
1999) of 395 women with breast cancer revealed that at five years there was a
significantly increased risk of death in women with a high score on the depression scale.
There was also a correlation for these women between risk of relapse or death in women
with high scores on the helplessness and hopelessness scale.
Peripheral Neuropathy and Depression
Pain severity from PN is associated with depression. A study reported in 2005
(Gore et al.) evaluated pain severity, pain-related interference with function, sleep
impairment, symptom levels of anxiety and depression, and quality of life among patients
with painful DPN. Results were based on patient self-reports. With PN, chronic pain,
sleep disturbance, and affective disorders often occur simultaneously and often do not
decline over time. The primary pain measure in this study looked at the severity of pain
on a 0 to 10 scale, and its interference with seven factors including general activity,
mood, walking ability, normal work, relations with others, and enjoyment of life. Results
showed that increases in pain resulted in increased difficulty in all seven areas. The
Hospital Anxiety and Depression Scale (HADS) measurement tool was used to assess
anxiety and depression in the patients. More than half of the patients indicated that they
were moderately or severely anxious or depressed.
Summary
The review of literature discusses empiric evidence supporting the relationships
between peripheral neuropathy and depression. When patients are depressed, judgment
may be impaired. Colleoni et al. (2000) showed that depression is a crucial factor for
initial acceptance of treatment. Sioka et al. (2008) demonstrated that the most common
8

chemotherapy treatments, including taxane-based, platinum-based and plant alkaloid
therapies, are all capable of causing neurotoxicity. Symptoms of PN may contribute to
depressive symptoms (Bakitas, 2007). This is also confirmed by Tolle et al. (2005), who
found that nearly half of patients who were suffering from diabetic peripheral neuropathy
were also taking medications for anxiety, depression, or sleep disturbances.
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Chapter Three Methods
This chapter presents the study methods. The chapter includes descriptions of the
sample, instrumentation, procedures, and data analysis for the study.
Sample
A sample of 30 adult patients receiving chemotherapy treatment with a taxanebased, platinum-based or plant alkaloid therapy was sought. Patients who had reported
numbness or tingling in their hands and/or feet were included in the study. Patients who
were treated for depression prior to chemotherapy were excluded from the study.
Patients with pre-existing PN from diabetes were excluded from the study.
Instrumentation
Beck Depression Inventory-Short Form (BDI-SF)
The Beck Depression Inventory-Short Form (BDI-SF) was developed in 2003
(Appendix A). It assesses the same symptoms as the original Beck Depression Form,
with a shorter, less burdensome format for the patients. Rather than the original 21
questions, the BDI-SF presents nine questions with four possible answers each. Total
scores range from zero to 36 with scores as follows: 0 to 10 is not depressed, 12 to 19 is
depressed and greater than 20 is very depressed (Furlanetto, Mendlowicz, & Bueno,
2005). Individual questions of the BDI-SF assess mood, pessimism, sense of failure, selfdissatisfaction, guilt, punishment, self-dislike, self-accusation, suicidal ideas, crying,
irritability, social withdrawal, body image, work difficulties, insomnia, fatigue, appetite,
10

weight loss, bodily preoccupation, and loss of libido. The BDI-SF was shown to be a
valid instrument for the identification of depression, with a sensitivity of 100% and
specificity of 83.1% (Furlanetto et al., 2005).
Overall Neuropathy Limitations Scale (ONLS)
The ONLS is a scale that is used to assess limitations and disability caused by
peripheral neuropathy (Appendix B). The ONLS is composed of two sections that total
12 questions. Items 1 to 6 assess neuropathy symptoms in the hands or arms, while items
7 to 12 assess the same symptoms in the legs and feet. Each question has three possible
responses that range from; not affected, affected but not prevented, to prevented. The
ONLS is calculated by adding the arm scale total and the leg scale total. The final score
can range from 0 (no disability) to 12 (maximum disability). Acceptable responsiveness
was shown with the ONLS (Graham, & Hughes, 2006).
Procedures
Patients from one outpatient facility were included in this study. After permission
was obtained from the facility to include patients in the study (Appendix C), the proposal
and permission letter were submitted to the USF Institutional Review Board for the
Protection of Human Subjects (Appendix D). Following approval, clinic staff identified
patients who reported numbness and tingling in their hands and/or feet. The study was
explained to the patients by the primary investigator and questions answered. The
patients signed the informed consent (Appendix E), a copy of the informed consent was
given to the patient, and he or she was asked to complete the study forms. The BDI-SF
was completed by the patient and the ONLS was administered by the primary
investigator. The primary investigator asked the questions on the ONLS and the patient
11

answered based on self-perception. Family members were present during the interview
with some of the study participants.
Data Analysis
The level of depression symptomatology and the limitations from peripheral
neuropathy symptoms experienced by cancer patients were statistically analyzed using
means and standard deviations. The relationship between depressive symptoms and
limitations of peripheral neuropathy in chemotherapy patients were analyzed using
Pearson correlation.
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Chapter Four Results, Discussion, and Conclusions
This chapter presents the data collection process and the results. The significance
of the study, the results, and the relevance to nursing are also discussed.
Results
The sample included 24 adult participants. Twenty-eight patients were approached
and four were excluded because of diabetes or diabetic neuropathy. Age range was 45-87
with the average participant age of 65 years. One participant was 100 years old. Of the
24 patients, 37.5% of them were on a single agent taxane-based drug, 37.5% of patients
were on a combination of a taxane-based drug with a platinum based drug, 16.6% of
patients were on a plant alkaloid, and 8.3% were on a combination of a taxane-based and
a non-neurotoxic chemotherapy drug. All patients had some symptoms of PN. The
sample was made up of 66.6% females, and 92% were Caucasian. (Table 1)
Beck Depression Inventory-Short Form (BDI-SF)
The BDI-SF is a patient self-report scale. Possible scores range from 0 to 36
where 0 to 10 is not depressed, 11 to 19 is depressed and greater than or equal to 20 is
very depressed. In this study the mean score was 4.125. The lowest score reported was
one and the highest score was 12. There was only one reported score of 12. (Table 2)
Overall Neuropathy Limitations Scale (ONLS)
The ONLS scale is calculated by adding the arm scale total and the leg scale total.
The final score can range from 0 (no disability) to 12 (maximum disability). In this
13

sample of 24 adults, the mean score was 2.2. The lowest score reported was zero and the
highest score was five. (Table 2)

Table 1. Frequencies and Percentages of Descriptive Demographic Data
Descriptive Demographic

Frequency

Percentage

Caucasian-Non-Hispanic

22

92%

Caucasian-Hispanic

2

8%

Male

8

33.3%

Female

16

66.6%

Ethnicity

Gender

Table 2. Means, Standard Deviations, and Ranges for Depression and Neuropathy Scores
Variable

N

Possible
Range

Sample
Range

Mean

Standard
Deviation

Beck Depression
Inventory

24

0-36

1-12

4.1

2.7

Overall Neuropathy
Limitations Scale

24

0-12

0-5

2.2

1.5

Discussion
Beck Depression Inventory-Short Form (BDI-SF)
The BDI-SF is short, and easy to read for patients. None of the participants
voiced confusion over any of the questions. On average it took patients three minutes to
14

complete the short form. The scores overall were low. With a possible range of 0 to 36
the mean score was 4.1. These results are not consistent with earlier studies reviewed.
Tolle et al. (2005) found that patients with peripheral neuropathy were so depressed they
required medications for anxiety, depression and sleep disturbances.
There are some limitations of the study. The small sample size, due to time
limitations, may have excluded some patients with worse symptoms. Also, patients
completing the form in the presence of loved ones may not have been truthful or honest
with their answers. Some patients do not want their family members to know if they are
having emotional difficulties. These limitations may have contributed to the low scores.
Overall Neuropathy Limitations Scale (ONLS)
The ONLS is a short survey. It was administered to the patient by the primary
investigator. On average it took patients five minutes to complete the scale.
With a possible range from 0 to 12 the mean score was 2.2. Patients with minimal
neuropathy symptoms were able to participate in the study, which may account for some
of the low scores. Patients had received an average of 5.9 cycles of chemotherapy, which
is a sufficient amount of time for neuropathy symptoms to present. Scores might be
higher if symptom severity were measured instead of interference with activity. Also, the
ONLS was administered by asking the patient about interference with the various
activities. Scores might have differed if the primary investigator were to observe the
patient doing the activities instead of relying on self-report.
Relationship Between Peripheral Neuropathy and Depression
The patients in this study did not show a significant relationship between their
neuropathy limitations and depression. Scores were low on both measures. This may
15

have contributed to the lack of correlation. These findings were not consistent with
previous studies.
Conclusions
A study might be done in the future with a few changes. First, the sample size
should be increased. This may be improved by collecting data over a longer period of
time. This would allow for a wider variety of patients with a wider array of physical and
mental symptoms. And second, the search criteria should include only patients with a
grade two or above PN. Potentially, these changes would increase scores and result in
more significant results.
It is important for nurses to understand the physical and mental effects that
chemotherapy can have on patients. Peripheral neuropathy can manifest in many
different ways and the limitations of ability to perform activities of daily living can be
devastating. It makes sense that the loss of autonomy would cause some depressive
symptoms. It is for this reason that patients need early detection of symptoms and
supportive care throughout chemotherapy treatment.

16

References

American Cancer Society (2010). Peripheral neuropathy caused by chemotherapy.
Retrieved May 28, 2010 via the World Wide Web: http://www.acsevents.org
Argoff, C., Cole, B., Fishbain, D., Irving, G., & Mmed, M. (2006). Diabetic peripheral
neuropathic pain: Clinical and quality-of-life issues. Mayo Clinic Proceedings,
81(4), S3-S11.
Bakitas, M. (2007). Background noise: The experience of chemotherapy-induced
peripheral neuropathy. Nursing Research, 56(5), 323-331.
Beuken, M.H.J., Rijke, J.M., Kessels, A.G., Schouten, H.C. Kleef, M., & Patijn, J.
(2007). Prevalence of pain in patients with cancer: a systematic review of the
past 40 years. Annals of Oncology, 18(9), 1437-1449.
Colleoni, M., Mandala, M., Peruzzotti, G., Robertson, C., Bredart, A., & Goldhirsch, A.
(2000). Depression and degree of acceptance of adjuvant cytotoxic drugs. The
Lancet, 356(9238), 1326-1327.
Davis, F.A. (2001). Taber’s cyclopedic medical dictionary (19th ed.). Philadelphia:
F.A. Davis Company.
Furlanetto, L., Mendlowicz, M., & Bueno, J., 2005. The validity of the BeckDepression Inventory-Short Form as a screening and diagnostic instrument for
moderate and severe depression in medical inpatients. Journal of Affective
Disorders, 86(1), 87-91.
Gore, M., Brandenburg, N., Dukes, E., Hoffman, D., Tai, K.S., & Stacey, B. (2005).
Pain severity in diabetic peripheral neuropathy is associated with patient
functioning, symptom levels of anxiety and depression, and sleep. Journal of
Pain and Symptom Management, 30(4), 374-385.
Graham, R.C., & Hughes, R.A.C. (2006). A modified peripheral neuropathy scale: The
Overall Neuropathy Limitations Scale. Journal of Neurology, Neurosurgery &
Psychiatry with Practical Neurology, 77(1), 973-976.
Gralla, R., Houlihan, N., & Messner, C. (2010). Understanding and managing
chemotherapy side effects. New York: CancerCare
Grohl, J. (2008). Depression. Psych Central. Retrieved May 27, 2010 via the World
Wide Web: http://psychcentral.com/disorders/depression

17

Hoffman, D., Sadosky, A., & Alvir, J. (2008). Cross-national burden of painful
diabetic peripheral neuropathy in Asia, Latin America, and the Middle East. Pain
Practice, 9(1), 35-42.
McManamy, J. (2009). Depression and cancer. Retrieved March 24, 2009 via the
World Wide Web: http://mcmanweb.com/article-43.htm
Miller, J., (2007). About Peripheral Neuropathy. The University of Chicago. Retrieved
January 11, 2010 via the World Wide Web: http://mikllercenter.uchicago.edu
Sioka, C., Kyritsis, A. (2009). Central and peripheral nervous system toxicity of
common chemotherapeutic agents. Cancer Chemotherapy Pharmacol, 63, 761767.
Stitham, S. (2008). Peripheral neuropathy. Retrieved May 28, 2010 via the World Wide
Web: http://www.nlm.nih.gov/medlineplus/ency/article/000593.html
Tolle, T., Xu, X., & Sadosky, A. (2006). Painful diabetic neuropathy: A crosssectional survey of health state impairment and treatment patterns. Journal of
Diabetes and its Complications, 20(1), 26-33.
Watson, M., Haviland, J.S., Greer, S., Davidson, J., Bliss, J.M. (1999). A psychological
response on survival in breast cancer: A population-based cohort study. Lancet,
354(9187), 1331-6.

18

Appendices

19

Appendix A: Beck Depression Inventory-Short Form

20

Appendix B: Overall Neuropathy Limitations Scale
OVERALL NEUROPATHY LIMITATIONS SCALE (ONLS)
Instructions: The examiner should question and observe the patient in order to determine the answers to the
following questions. Note should be made of any other disorder other than peripheral neuropathy which
limits function at the foot of the page.
ARM SCALE
Does the patient have any symptoms in their hands or arms; e.g. Tingling, numbness or weakness? Yes
No
Is the patient affected in their ability to:
Prevented

Not affected

Affected but not prevented

Wash and brush their hair
Turn a key in a lock
Use a knife and fork together
Do or undo buttons or zips
Dress the upper part of their body
excluding buttons or zips
If all these functions are prevented can the patient make purposeful movements with their hands or arms?
Yes
No
Arm Grade
0= Normal
1= Minor symptoms in one or both arms but not affecting any of the functions listed
2= Disability in one or both arms affecting but not preventing any of the functions listed
3= Disability in one or both arms preventing at least one but not all functions listed
4= Disability in both arms preventing all functions listed but purposeful movement still possible
5= Disability in both arms preventing all purposeful movements
SCORE=_____
LEG SCALE
Yes
Does the patient have difficulty running or climbing stairs?
Does the patient have difficulty with walking?
Does their gait look abnormal?
How do they mobilize for about 10 meters (33 feet)?
Without aid
With one stick or crutch or holding to someone’s arm
With two sticks or crutches or one stick or
Crutch holding onto someone’s arm or frame
With a wheelchair
21

No

N/A

If they use a wheelchair, can they stand and walk 1 meter with
the help of one person?
If they cannot walk as above are they able to make some purposeful
Movements of their legs; e.g. reposition legs in bed?
Does the patient use ankle or foot braces?
Leg Grade
0= Walking/climbing stairs/running not affected
1= Walking/climbing stairs/running is affected, but gait does not look abnormal
2= Walks independently but gait looks abnormal
3= Requires unilateral support to walk 10 meters (stick, single crutch, one arm)
4= Requires bilateral support to walk 10 meters (sticks, crutches, crutch and arm, frame)
5= Requires wheelchair to travel 10 meters but able to stand and walk 1 meter with the help of one person
6= Restricted to wheelchair, unable to stand and walk 1 meter with the help of one person, but able to make
some purposeful leg movements
7= Restricted to wheelchair or bed most of the day, unable to make any purposeful movements of the legs
Overall Neuropathy Limitations Scale=arm scale (range 0 to 5) + leg scale (range 0 to 7)
Range 0 (no disability) to 12 (maximum disability)
TOTAL
SCORE=_____
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Appendix C: Letter of Approval Florida Cancer Institute-New Hope
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Appendix D: Letter of Approval USF Institutional Review Board
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Appendix E: Informed Consent

Informed Consent to Participate in Research
Information to Consider Before Taking Part in this Research Study
IRB Study # Pro00000265
Researchers at the University of South Florida (USF) study many topics. To do this, we need the help of
people who agree to take part in a research study. This form tells you about this research study.

We are asking you to take part in a research study that is called:
The Correlation Between Neuropathy Limitations and Depression in Chemotherapy Patients.
The person who is in charge of this research study is Melissa Thebeau, RN, OCN. This person is called the
Principal Investigator. However, other research staff may be involved and can act on behalf of the person
in charge.
The research will be done at Florida Cancer Institute-New Hope in New Port Richey, Fl.

Purpose of the study
The purpose of this study is to:
• The purpose of this study is to find a correlation between chemotherapy-induced peripheral
neuropathy and depression in chemotherapy patients. Peripheral Neuropathy is nerve damage in
your arms and legs and can cause pain numbness and tingling in those body parts.
• The study is being conducted by a USF graduate nursing student. All data collection and analysis
will be overseen by a USF instructor.
Study Procedures
If you take part in this study, you will be asked to:
• 1) Sign this informed consent stating voluntary willingness to participate in the study.
• 2) Complete the two brief questionnaires: The Beck Depression Scale and the Overall Neuropathy
Limitations Scale.
• 3) The questionnaires will be completed in the chemotherapy infusion room.
• 4) This one visit is all that is required for this study. No follow-up visits or phone calls will be
made.
• 5) No audio or videotaping will be used. All forms are confidential and do not contain any
personal demographic information.
• 6) If serious depression levels are found, patient may be referred to appropriate resources.
Alternatives
You have the alternative to choose not to participate in this research study.
Benefits
The benefit of this study includes evaluation of your depression status. If depression is found, referral to
appropriate resources may be made.
Risks or Discomfort
Risks in this study include any personal discomfort during the interview used to complete the depression
survey.
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Compensation

We will not pay you for the time you volunteer while being in this study.

Conflict of Interest Statement
There is no conflict of interest involving the principal investigator in this
study.
Privacy and Confidentiality

We must keep your study records private and confidential; however, certain people may
need to see your study records. By law, anyone who looks at your records must keep
them completely confidential. The only people who will be allowed to see these records
are:
•

The research team, including the Principal Investigator, study coordinator,
research nurses, and all other research staff.

•

Certain government and university people who need to know more about the
study. For example, individuals who provide oversight on this study may need to
look at your records. This is done to make sure that we are doing the study in the
right way. They also need to make sure that we are protecting your rights and
your safety.) These include:
o

o
•

The University of South Florida Institutional Review Board (IRB) and the
staff that work for the IRB. Other individuals who work for USF that
provide other kinds of oversight may also need to look at your records.
The Department of Health and Human Services (DHHS).

Confidentiality may be broken if there is suspicion of threat of harm to self or others. This
information would be found during the completion of the Beck Depression Inventory.

We may publish what we learn from this study. If we do, we will not let anyone know
your name. We will not publish anything else that would let people know who you are.
Voluntary Participation / Withdrawal

You should only take part in this study if you want to volunteer. You should not feel that
there is any pressure to take part in the study, to please the investigator or the research
staff. You are free to participate in this research or withdraw at any time. There will be
no penalty or loss of benefits you are entitled to receive if you stop taking part in this
study.
New information about the study
During the course of this study, we may find more information that could be important to you. This
includes information that, once learned, might cause you to change your mind about being in the
study. We will notify you as soon as possible if such information becomes available.
Questions, concerns, or complaints

If you have any questions, concerns or complaints about this study, call the Melissa
Thebeau, RN, OCN, primary investigator at 727-505-8393.
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If you have questions about your rights as a participant in this study, general questions, or
have complaints, concerns or issues you want to discuss with someone outside the
research, call the Division of Research Integrity and Compliance of the University of
South Florida at (813) 974-9343.
Consent to Take Part in this Research Study

It is up to you to decide whether you want to take part in this study. If you want to take
part, please sign the form, if the following statements are true.
I freely give my consent to take part in this study. I understand that by signing this
form I am agreeing to take part in research. I have received a copy of this form to take
with me.
_____________________________________________
Signature of Person Taking Part in Study
_____________________________________________
Printed Name of Person Taking Part in Study
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____________
Date

